Altered cyclin-dependent kinase activity is observed in many human malignancies. Cyclin-dependent kinases that promote cell cycle progression may be promising targets in the treatment of cancer. The therapeutic effects of roniciclib, a cyclin-dependent kinase inhibitor for medullary thyroid cancer were investigated in the present study. Roniciclib inhibited medullary thyroid cancer cell proliferation in a dose-dependent manner. Roniciclib induced caspase-3 activity and contributed to apoptosis. Cell cycle progression was arrested in the G2 phase. , roniciclib treatment retarded the growth of tumors of medullary thyroid cancer xenografts. In addition, roniciclib in combination with sorafenib was more effective than either single treatment in a xenograft model. No morbidity was observed in animals treated with single roniciclib therapy and combination treatment of roniciclib and sorafenib. These data provide a rationale for clinical assessment of using roniciclib in the treatment of patients with medullary thyroid cancer.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6021325 | PMC |
http://dx.doi.org/10.18632/oncotarget.25555 | DOI Listing |
World J Surg Oncol
January 2025
Department of Thoracic Surgery, University Hospitals Birmingham, Birmingham, UK.
A 34-year-old male patient with recently diagnosed with medullary thyroid carcinoma underwent total thyroidectomy and radical neck dissection, requiring sharp dissection to separate the tumour from the trachea. He required post operative intubation due to bilateral vocal cord paralysis. He developed ischaemic necrosis of the upper two thirds of the trachea presenting with marked surgical emphysema and an infective wound.
View Article and Find Full Text PDFJ Nucl Med
January 2025
Department of Nuclear Medicine, Medical University of Innsbruck, Innsbruck, Austria
Several exploratory studies have demonstrated the feasibility of cholecystokinin-2 receptor (CCK2R) targeting in patients with medullary thyroid carcinoma (MTC) and other neuroendocrine tumors (NETs). We report the results of a prospective phase I/IIA pilot study (clinicaltrials.gov NCT06155994) conducted at our center with the Ga-labeled peptide analog DOTA-DGlu-Ala-Tyr-Gly-Trp-(N-Me)Nle-Asp-1-Nal-Phe-NH (Ga-DOTA-MGS5).
View Article and Find Full Text PDFJ Clin Transl Endocrinol
March 2025
Department of Ultrasound, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai 200072, PR China.
Objectives: This study aimed to evaluate the diagnostic performance for medullary thyroid cancer (MTC) based on the 2017 Thyroid Imaging Reporting and Data System by the American College of Radiology (ACR TI-RADS) guideline, and the ability to recommend fine needle aspiration (FNA) for MTC.
Methods: Fifty-six MTCs were included, and 168 benign thyroid nodules (BTNs) and 168 papillary thyroid nodules (PTCs) were matched according to age. Ultrasound (US) features were reviewed according to ACR TI-RADS.
Oncol Lett
March 2025
Department of Oncology, Affiliated Hospital of Shandong Second Medical University, Weifang, Shandong 261042, P.R. China.
A hyalinizing trabecular tumor (HTT), characterized by a trabecular growth pattern and notable hyalinization within the trabeculae, occurs at a rate of ~1%. As patients with HTT may be asymptomatic, accurate diagnosis is a challenge. Due to its resemblance to other tumors, such as papillary thyroid carcinoma and medullary thyroid carcinoma, a precise diagnosis necessitates both pathological and molecular examinations.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!